Company Overview and News

12
Market Live: Nifty extends losses, Sensex breaks 35,000; RIL, HDFC, Infosys, ITC drag

2018-05-04 moneycontrol
Services PMI: India’s service sector continued to improve at the start of the quarter, with business activity rising at a faster pace, supported by new order growth. Reflecting improvements in demand conditions, job creation accelerated to the sharpest since March 2011. Inflationary price pressures continued to ease further, with input and output charge inflation registering below their respective historical averages, Nikkei IHS Markit said.
BAJAJ-AUTO 500325 500820 500425 533150 533096 RELIANCE 532617 HFCL 532977 BHRQY AMBUJACEM ASIANPAINT JSWENERGY CSLQY 532541 AMBUY RIGD BJJQY 500412 BHARTIARTL RLNIY 500034 500870 NIITTECH HINDALCO JETAIRWAYS HEXAWARE 532129 533148 TIRUMALCHM HNDNF 532454 500183 CASTROLIND GODREJPROP BAJFINANCE 534809 ADANIPOWER PCJEWELLER 500440

6
Market Live: Sensex, Nifty open lower on global weakness; Bharti Airtel jumps

2018-05-04 moneycontrol
Rupee Update: The rupee edged 2 paise lower to 62.66 against the US dollar after opening one paisa higher after the greenback weakened overseas ahead of monthly US jobs report and China-US trade meet outcome.
533096 532617 JETAIRWAYS HFCL HEXAWARE BHRQY 532129 JSWENERGY 533148 CSLQY TIRUMALCHM 532454 500183 CASTROLIND BAJFINANCE BJJQY 534809 ADANIPOWER PCJEWELLER 500412 BHARTIARTL 500034 500870

0
HFCL rises 3% on order win from BSNL; Q4 PAT jumps 86%

2018-05-04 moneycontrol
Share price of Himachal Futuristic Communication (HFCL) rose 3 percent in the early trade on Friday on the back of order win from BSNL and strong fourth quarter numbers.
500183 HFCL

0
Vanu India-HFCL bag Rs 579-cr project from BSNL in northeast region

2018-05-03 moneycontrol
Telecom gear firm Himachal Futuristic Communications Limited (HFCL) and Vanu India have jointly bagged a telecom network rollout project worth Rs 579 crore in the northeast region from state-run firm BSNL.
500183 HFCL

0
Himachal Futuristic Communications Limited - Press Release

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500183 HFCL

0
Himachal Futuristic Communications Limited - Dividend

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500183 HFCL

0
Himachal Futuristic Communications Limited - Financial Result Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500183 HFCL

0
Himachal Futuristic Communications Limited - Outcome of Board Meeting

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500183 HFCL

0
Himachal Futuristic Communications Limited - Statement of deviation(s) or variation(s) under Reg. 32

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500183 HFCL

0
Himachal Futuristic Communications Limited - Trading Window

2018-04-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500183 HFCL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...